公开(公告)号：US09764131B2

公开(公告)日：2017-09-19

申请号：US14755840

申请日：2015-06-30

Applicant: InCube Labs, LLC

Inventor： Mir Imran ,  Mir Hashim ,  Glen McLaughlin ,  Huma Arastu ,  Rekha Vaidyanathan ,  Joel Harris ,  Radhika Korupolu ,  Andrew Mangogna ,  Chang Ong ,  Sanjay Patel ,  Lu Wang ,  Timothy Williams

IPC: A61N1/30 ,  A61N1/32 ,  A61N1/04 ,  A61K9/00 ,  A61K31/4178 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/5415

CPC classification number: A61N1/325 ,  A61K9/0009 ,  A61K9/0014 ,  A61K31/4178 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/5415 ,  A61N1/0436 ,  A61N1/044 ,  A61N1/0448 ,  A61N1/30 ,  A61N1/303

Abstract: Various embodiments provide methods and systems for the biphasic iontophoretic transdermal delivery of therapeutic agents. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient. Embodiments may be used for delivery of agents which cause adverse effects from unwanted passive diffusion.

公开(公告)号：US09763922B2

公开(公告)日：2017-09-19

申请号：US14952821

申请日：2015-11-25

Applicant: Genentech, Inc. ,  Constellation Pharmaceuticals, Inc.

Inventor： Marc Adler ,  Brian K. Albrecht ,  Sarah Bronner ,  Kevin X. Chen ,  Alexandre Côté ,  Terry Crawford ,  Patrick Cyr ,  Jackson Egen ,  Steven Kauder ,  Kwong Wah Lai ,  Jiangpeng Liao ,  Steven Magnuson ,  Jeremy Murray ,  Richard Pastor ,  F. Anthony Romero ,  Alexander M. Taylor ,  Vickie Hsiao-Wei Tsui ,  Fei Wang ,  Bing-Yan Zhu

IPC: A61K31/437 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/55 ,  C07D471/04 ,  C07D519/00 ,  A61K45/06

CPC classification number: A61K31/437 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/55 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

公开(公告)号：US20170252302A1

公开(公告)日：2017-09-07

申请号：US15449798

申请日：2017-03-03

Applicant: CHARLESTON LABORATORIES, INC.

Inventor： Paul BOSSE ,  John AMELING ,  William KOZAREK ,  Bernard SCHACHTEL ,  John HIGGINS

IPC: A61K9/48 ,  A61K31/4045 ,  A61K31/5415 ,  A61K9/16

CPC classification number: A61K9/4808 ,  A01N43/42 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/4045 ,  A61K31/44 ,  A61K31/5415 ,  A61K2300/00

Abstract: Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with the headache. Also provided herein are small smooth particulates comprising a 5HT1B/1D receptor agonist. Compositions for oral administration are described herein wherein the compositions comprise a combination of active agents, such as a 5HT1B/1D receptor agonist and one or more antiemetics.

公开(公告)号：US20170246177A1

公开(公告)日：2017-08-31

申请号：US15521804

申请日：2015-10-27

Applicant: UNIVERSITY OF MARYLAND

Inventor： Kan CAO

IPC: A61K31/5415 ,  A61K8/49 ,  A61K31/436 ,  A61K8/06 ,  A61K9/00 ,  A61Q19/10 ,  A61Q19/00 ,  A61Q19/08 ,  A61K9/107

CPC classification number: A61K31/5415 ,  A61K8/06 ,  A61K8/49 ,  A61K8/4926 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/10 ,  A61K9/107 ,  A61K31/436 ,  A61K2800/92 ,  A61P17/00 ,  A61Q19/00 ,  A61Q19/08 ,  A61Q19/10 ,  A61K2300/00

Abstract: A method of alleviating age-related symptoms in a mammal, which comprises a step of administering to a mammal in need thereof, an effective amount of a composition containing an effective amount of at least methylene blue.

公开(公告)号：US09724294B2

公开(公告)日：2017-08-08

申请号：US13564525

申请日：2012-08-01

Applicant: Jay Richard Ray, II ,  Charles D. Hodge

Inventor： Jay Richard Ray, II ,  Charles D. Hodge

IPC: A61K31/54 ,  A61K9/00 ,  A61K31/5415 ,  A61K31/167 ,  A61K31/53 ,  A61K31/7048 ,  A61K9/06

CPC classification number: A61K9/0014 ,  A61K9/06 ,  A61K31/167 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/63

Abstract: The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. For instance, the transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, and/or other active ingredients. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.

公开(公告)号：US20170216441A1

公开(公告)日：2017-08-03

申请号：US15486418

申请日：2017-04-13

Applicant: CutisPharma, Inc.

Inventor： Indu Muni

IPC: A61K47/34 ,  A61K31/573 ,  A61K9/06 ,  A61K31/568 ,  A61K47/06 ,  A61K31/192 ,  A61K47/24 ,  A61K31/167 ,  A61K31/137 ,  A61K31/245 ,  A61K31/58 ,  A61K33/08 ,  A61K31/138 ,  A61K31/565 ,  A61K31/566 ,  A61K31/57 ,  A61K31/04 ,  A61K47/10

CPC classification number: A61K47/34 ,  A61J1/00 ,  A61J3/00 ,  A61K9/0014 ,  A61K9/0095 ,  A61K9/06 ,  A61K31/00 ,  A61K31/04 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/245 ,  A61K31/46 ,  A61K31/5415 ,  A61K31/565 ,  A61K31/566 ,  A61K31/568 ,  A61K31/57 ,  A61K31/573 ,  A61K31/58 ,  A61K33/08 ,  A61K47/06 ,  A61K47/10 ,  A61K47/24

Abstract: The invention provides compositions and methods for the convenient compounding of pharmaceuticals. Single and multiple unit of use kits are provided which contain all the necessary components required for preparing a compounded pharmaceutical. The kits of the invention include a first container having a first active agent and a second container having at least one second inactive agent. The kits of the invention are also useful for compounding veterinary pharmaceuticals.

公开(公告)号：US20170209456A1

公开(公告)日：2017-07-27

申请号：US15419763

申请日：2017-01-30

Applicant: WisTa Laboratories Ltd.

Inventor： John Mervyn David STOREY ,  James Peter SINCLAIR ,  Colin MARSHALL ,  Han Wan TAN ,  Claude Michel WISCHIK

IPC: A61K31/5415 ,  G01N33/52 ,  A61K49/00

CPC classification number: A61K31/5415 ,  A61K9/0019 ,  A61K49/006 ,  C07D279/18 ,  C09B19/02 ,  G01N33/52 ,  Y02A50/393

Abstract: This disclosure pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). Also disclosed resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.

公开(公告)号：US20170165203A1

公开(公告)日：2017-06-15

申请号：US15387541

申请日：2016-12-21

Applicant: ICEUTICA PTY LTD.

Inventor： Aaron Dodd ,  H. William Bosch ,  Felix Meiser ,  Marck Norret ,  Adrian Russell

IPC: A61K9/16 ,  B02C17/20 ,  A01N37/38 ,  A61K31/122 ,  A61K31/415 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/198 ,  A61K38/13 ,  A61K31/196 ,  A01N57/20 ,  A01N47/36 ,  A61K31/404 ,  A01N55/02 ,  A61K31/5415 ,  A61K31/421 ,  A61K31/192 ,  A61K31/57 ,  A61K31/137 ,  A61K33/04 ,  A01N25/10 ,  A01N25/12 ,  A61J3/02 ,  A23L33/10 ,  A23P10/20 ,  B02C19/00

CPC classification number: A61K9/1682 ,  A01N25/10 ,  A01N25/12 ,  A01N25/34 ,  A01N37/38 ,  A01N47/36 ,  A01N55/02 ,  A01N57/20 ,  A23L33/10 ,  A23P10/20 ,  A23P10/30 ,  A23V2002/00 ,  A61J3/02 ,  A61K9/0075 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K31/122 ,  A61K31/137 ,  A61K31/18 ,  A61K31/192 ,  A61K31/196 ,  A61K31/198 ,  A61K31/404 ,  A61K31/405 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/565 ,  A61K31/57 ,  A61K33/04 ,  A61K38/13 ,  B02C17/20 ,  B02C19/0056 ,  A01N39/04 ,  A01N47/14 ,  A01N57/12 ,  A01N59/02

Abstract: The present invention relates to methods for producing nanoparticle and microparticle powders of a biologically active material which have improved powder handling properties making the powders suitable for commercial use using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.

公开(公告)号：US09662391B2

公开(公告)日：2017-05-30

申请号：US12156949

申请日：2008-06-05

Applicant: Roderick A. Hyde ,  Muriel Y. Ishikawa ,  Eric C. Leuthardt ,  Royce A. Levien ,  Robert W. Lord ,  Mark A. Malamud ,  Elizabeth A. Sweeney ,  Lowell L. Wood, Jr. ,  Victoria Y. H. Wood

Inventor： Roderick A. Hyde ,  Muriel Y. Ishikawa ,  Eric C. Leuthardt ,  Royce A. Levien ,  Robert W. Lord ,  Mark A. Malamud ,  Elizabeth A. Sweeney ,  Lowell L. Wood, Jr. ,  Victoria Y. H. Wood

IPC: A61M5/172 ,  A61K45/06 ,  A61K31/135 ,  A61K31/5415 ,  A61K33/00 ,  G06F19/00 ,  G06Q50/22 ,  G06Q50/24

CPC classification number: A61K45/06 ,  A61K31/135 ,  A61K31/5415 ,  A61K33/00 ,  G06F19/00 ,  G06F19/3456 ,  G06Q50/22 ,  G06Q50/24 ,  A61K2300/00

Abstract: Combination therapeutics, computer program products, and systems are described that include at least one combined prescription psychiatric medication and at least one artificial sensory experience for ameliorating at least one side effect of the psychiatric medication.

公开(公告)号：US20170136029A1

公开(公告)日：2017-05-18

申请号：US15418572

申请日：2017-01-27

Applicant: The Scripps Research Institute ,  IRM LLC

Inventor： Peter Schultz ,  Luke Lairson ,  Vishal Deshmukh ,  Costas Lyssiotis

IPC: A61K31/5415 ,  A61K31/495 ,  A61K31/46 ,  A61K31/137 ,  A61K31/216 ,  A61K31/40

CPC classification number: A61K31/5415 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/216 ,  A61K31/40 ,  A61K31/439 ,  A61K31/46 ,  A61K31/495 ,  A61K38/215 ,  A61K39/3955

Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.